Teva Gets $225M DOJ Penalty, Glenmark $30M, for Price Fixing Critical Generic Drugs

The Department of Justice (DOJ) has resolved criminal antitrust charges against Teva Pharmaceuticals and Glenmark Pharmaceuticals for price fixing with deferred prosecution agreements, hefty fines, admission that the DOJ’s facts are true and a requirement to divest key lines of business.
Source: Drug Industry Daily

Leave a Reply